A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on
symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness.
Approximately 48 participants will take part in the study across the United States.
The study treatment (NLS-2 or placebo) will be administered for 8 weeks. After this treatment
period, the participant may have the option to participate in a separate long-term extension
study during which all participants will be treated with NLS-2.